FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB
Executive Summary
The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.
You may also be interested in...
Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.
Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?
Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.
Glaxo SmithKline EU Merger Approval Includes Potential Divestment Of Ariflo
Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.